Aiming for CLIA Certification, DermTech Begins Validation of Melanoma Test | GenomeWeb

DermTech said this week that it has begun commercial validation testing of its proprietary pigmented lesion assay, a non-invasive qPCR-based test for melanoma.

The San Diego-based company recently completed the build-out of a commercial laboratory space in nearby La Jolla, Calif. The company needs to complete analytical and clinical validation studies of its assay in order to receive regulatory certification under CLIA requirements.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.

Clinicians look to fold non-medical data into algorithms to predict patients' health, the Wall Street Journal reports.

Connecticut's biotech investment is leading to the building of labs to house new startups, the Associated Press reports.

Craig Venter's Health Nucleus aims to change preventive medicine, according to the Robb Report.